AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27090917
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection at the outer thigh
Trial: 27091189
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment in Korean MDD patients
Trial: 27091189
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment in STAR*D level 1 (n=1677)
Trial: 27091421
Drug: LFA102 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFA102 at 60 mg/kg intravenously once every 4 weeks
Trial: 27091847
Drug: Surgical or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical or catheter-based treatment of VSD (5.2% of cases, 181 children)
Trial: 27091847
Drug: Isolated VSDs
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated VSDs (no treatment specified)
Trial: 27092197
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (dabigatran), taken twice daily (bid) according to label recommendation
Trial: 27092830
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks
Trial: 27093291
Drug: Intravaginal ring
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal ring delivering 150 mg DL-lactic acid for 7 days
Trial: 27093291
Drug: Intravaginal ring
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal ring delivering 150 mg DL-lactic acid
Trial: 27093365
Drug: Pembrolizumab (anti-PD-1)
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab (anti-PD-1) at a dose of 2 mg/kg every 3 weeks
Trial: 27094489
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral aspirin and folic acid
Trial: 27095043
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine challenge dose (10μg HBs antigen)
Trial: 27096100
Drug: Intranodal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranodal and intradermal backup options
Trial: 27096100
Drug: Intranodal route
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRANODAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranodal route of DC vaccines
Trial: 27098749
Drug: BMX-001 (manganese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMX-001 (manganese porphyrin) administered subcutaneously
Trial: 27099175
Drug: Nav1.7 sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nav1.7 sodium channel blocker (new potent and selective compound)
Trial: 27099175
Drug: Nav1.7 blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nav1.7 blockers (including clinical test agent)
Trial: 27103349
Drug: GSK2126458 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2126458 (a novel, potent PI3K/mTOR inhibitor)
Trial: 27106070
Drug: Intradetrusor onabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intradetrusor onabotulinumtoxinA (BoNT-ONA) injections
Trial: 27106966
Drug: New score
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New score based on two retained STOP-BANG questions (treatment for hypertension and neck circumference >40 cm)
Trial: 27108080
Drug: Accelerated hypofractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hypofractionated three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, combined with platinum doublet chemotherapy
Trial: 27109549
Drug: Sunitinib 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 15 mg/m2 orally once daily for 4 weeks every 6 weeks
Trial: 27110377
Drug: Routine non-invasive
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine non-invasive management with optimal medical therapy
Trial: 27110385
Drug: Abatacept 125
RxNorm normalized name: abatacept 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 125 mg weekly with background methotrexate
Trial: 27110385
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg bi-weekly with background methotrexate
Trial: 27111235
Drug: High CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CAR-T cell doses and tumor burden
Trial: 27111235
Drug: Risk-stratified CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-stratified CAR-T cell dosing based on BM disease burden
Trial: 27111344
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no drugs administered during follow-up)
Trial: 27112607
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers use
Trial: 27112607
Drug: Death or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Death or treatment withdrawal due to terminal status
Trial: 27114712
Drug: SIJ fusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SIJ fusion using iFuse Implant System(®)
Trial: 27115431
Drug: Abbott HCV
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbott HCV core antigen (cAg) assay with a clinical cutoff of 10 fmol/l
Trial: 27116013
Drug: MLS(®) laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLS(®) laser therapy (LT) - 6 sessions, beam area 19.635 cm², 0.168 W/cm², 4 J/cm², starting at fraction 20 of radiotherapy
Trial: 27116013
Drug: MLS(®) laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLS(®) laser therapy (LT)
Trial: 27116183
Drug: Foretinib 60
RxNorm normalized name: Foretinib
DrugBank: Foretinib (DB12307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foretinib 60 mg po daily
Trial: 27116379
Drug: Icatibant (self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icatibant (self-administered for 62.3% of attacks, healthcare professional-administered for 37.7%)
Trial: 27118284
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment (Group 1)
Trial: 27118540
Drug: Flavopiridol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavopiridol (30 mg/m² loading dose followed by 30 mg/m² infusion once weekly for 3 weeks every 5 weeks for 2 cycles)
Trial: 27121782
Drug: SB-756050 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-756050 (various doses)
Trial: 27121782
Drug: SB-756050 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-756050 (two lowest doses)
Trial: 27121782
Drug: SB-756050 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-756050 (two highest doses)
Trial: 27121782
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg single dose on Day 6)
Trial: 29728798
Drug: Irinotecan-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan-based chemotherapy
Trial: 27124184
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication usage
Trial: 27124486
Drug: Dabrafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabrafenib (150 mg, twice daily) and trametinib (2 mg/d) continuously until disease progression or intolerance
Trial: 27124486
Drug: Dabrafenib and
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib and trametinib treatment
Trial: 27124835
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg daily for 21 days every 28 days)
Trial: 27125892
Drug: Liletta® 52-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liletta® 52-mg IUS
Trial: 27128233
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg, followed by 200 mg QD for days 2-7) plus tofacitinib (30 mg on day 5)
Trial: 27128233
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg QD for days 1-3) plus tofacitinib (10 mg on day 3)
Trial: 27128614
Drug: sirolimus (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sirolimus (1-4 mg daily oral maintenance doses)
Trial: 27128675
Drug: Artemether-lumefantrine (days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (days 0-2) plus single dose primaquine (0.75mg/kg on day 2) for P. falciparum infections
Trial: 27129117
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg single dose in subjects with mild hepatic impairment
Trial: 27129117
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg single dose in subjects with moderate hepatic impairment
Trial: 27129325
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy (GT) using an autologous CD34(+)-enriched cell fraction transduced with a retroviral vector encoding human ADA cDNA (GSK2696273)
Trial: 27130222
Drug: blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blood pressure augmentation
Trial: 27130222
Drug: cell-based therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cell-based therapies
Trial: 27133664
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 mcg b.i.d.)
Trial: 27133759
Drug: Nintedanib 200mg
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib 200mg BID daily in a 4-week cycle until progression or intolerable toxicity
Trial: 27135612
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine (40 mg/m2 on day 1 and 8) with erlotinib (100 mg daily) in the CSV group (N = 16)
Trial: 27135612
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine (100 mg/week) with erlotinib (100 mg daily) in the MSV group (N = 14)
Trial: 27135612
Drug: Vinorelbine co-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine co-administration in the CSV group
Trial: 27135612
Drug: Vinorelbine co-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine co-administration in the MSV group
Trial: 27136905
Drug: Migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Migalastat HCl 150 mg (single oral dose)
Trial: 27136910
Drug: Oral canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral canagliflozin 300 mg
Trial: 27136910
Drug: Intravenous [(14)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous [(14) C]-canagliflozin 10 µg
Trial: 27137149
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg once daily on days 1 and 6, twice daily on days 2-5
Trial: 27137427
Drug: Escitalopram, sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, sertraline, or venlafaxine extended-release, open-label treatment for 8 weeks
Trial: 27137427
Drug: Escitalopram and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram and sertraline
Trial: 27138310
Drug: Non-Vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Vitamin K antagonist oral anticoagulants (NOAC)
Trial: 27138628
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation at varying doses (50 to 750 mg kg(-1) day(-1))
Trial: 27139036
Drug: Cixutumumab 6
RxNorm normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab 6 mg/kg q2w
Trial: 27139036
Drug: Cixutumumab 10
RxNorm normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab 10 mg/kg q2w
Trial: 27139036
Drug: Cixutumumab 15
RxNorm normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab 15 mg/kg q3w
Trial: 27139036
Drug: Cixutumumab 20
RxNorm normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab 20 mg/kg q3w
Trial: 27139473
Drug: β-lactam/β-lactamase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactam/β-lactamase inhibitor (BLBLI) combinations in the empirical-therapy cohort (ETC)
Trial: 27139473
Drug: Carbapenems in
RxNorm normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenems in the empirical-therapy cohort (ETC)
Trial: 27139473
Drug: β-lactam/β-lactamase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactam/β-lactamase inhibitor (BLBLI) combinations in the targeted-therapy cohort (TTC)
Trial: 27139473
Drug: Carbapenems in
RxNorm normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenems in the targeted-therapy cohort (TTC)
Trial: 27139805
Drug: Investigational trivalent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational trivalent GBS vaccine (20 μg dose, two injections, 1 month apart)
Trial: 27139805
Drug: Investigational trivalent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational trivalent GBS vaccine (0.5 μg, 2.5 μg, or 5.0 μg doses, one injection at 28-35 weeks' gestation)
Trial: 27139805
Drug: Investigational trivalent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational trivalent GBS vaccine (various doses)
Trial: 27140229
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily with deleobuvir 800 mg twice daily (b.i.d.) and weight-based ribavirin for 24 weeks
Trial: 27140229
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily with deleobuvir 600 mg three times daily (t.i.d.) and weight-based ribavirin for 24 weeks
Trial: 27140401
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron infusion
Trial: 27140533
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk insulin
Trial: 27140533
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk leptin and insulin
Trial: 27142174
Drug: Guideline-indicated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-indicated care (including dietary advice, smoking cessation advice, P2Y12 inhibitors, coronary angiography)
Trial: 27142184
Drug: Autofluorescence bronchoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autofluorescence bronchoscopy (AFB) in addition to low-dose CT (LDCT) scan
Trial: 27142184
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT (LDCT) scan
Trial: 27142472
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide (ASO) administered as an intravenous infusion over 1-2 hours daily for 4 days in week 1 and for 2 days in weeks 2-6 of an 8-week cycle.
Trial: 27142472
Drug: Cisplatin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (3 mg/kg i.p. weekly) tested in PDX derived from platinum-sensitive SCLC.
Trial: 27142472
Drug: Cisplatin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (3 mg/kg i.p. weekly) tested in PDX derived from platinum-refractory SCLC.
Trial: 27142672
Drug: Hypocaloric hyperproteic
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric hyperproteic diet (HHD), ~1000 kcal/day, ~125 g protein/day for 3 weeks
Trial: 27143353
Drug: Leptin antagonist
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin antagonist applied locally to the ascending aorta in AngII-infused mice.
Trial: 27145310
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment (nonantibiotic) consisting of mild analgesics (nonsteroidal anti-inflammatory drug or paracetamol)
Trial: 27145310
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment (nonantibiotic)
Trial: 27146701
Drug: Implants (10,096
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants (10,096 total)
Trial: 27146701
Drug: Antidepressants intake
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants intake
Trial: 27146799
Drug: Exenatide Once
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide Once Weekly (QW)
Trial: 27148452
Drug: CC-486 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (300 mg once daily for the first 21 days of 28-day treatment cycles)
Trial: 27148452
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for the first 21 days of 28-day treatment cycles)
Trial: 27149114
Drug: PPV23 (23-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPV23 (23-valent pneumococcal polysaccharide vaccine) administered intramuscularly as a single dose
Trial: 27150464
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) or treatment as usual (TAU)
Trial: 27150686
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonists (H2RAs) used by 313 participants
Trial: 27150686
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonists (H2RAs)
Trial: 27150686
Drug: Non-use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-use of H2 receptor antagonists (H2RAs)
Trial: 27151914
Drug: Cell-assisted lipotransfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell-assisted lipotransfer using freshly isolated autologous adipose-derived stromal cells (4.07 × 10(7) cells with 10 ml of lipoaspirate)
Trial: 27151994
Drug: Entinostat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat (10 or 15 mg oral entinostat once every other week)
Trial: 27151994
Drug: Entinostat (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat (15 mg oral entinostat once weekly in 3 of 4 weeks)
Trial: 27152857
Drug: Chemotherapy during
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy during radiation for PET nonresponders who changed chemotherapy (38 patients)
Trial: 27152857
Drug: Chemotherapy during
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy during radiation for PET responders (113 patients)
Trial: 27152857
Drug: Chemotherapy during
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy during radiation for PET nonresponders who did not change chemotherapy (50 patients)
Trial: 27152857
Drug: PET nonresponders
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET nonresponders who did not change chemotherapy (50 patients)
Trial: 27152857
Drug: PET nonresponders
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET nonresponders who changed chemotherapy (38 patients)
Trial: 27153246
Drug: faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: faldaprevir 120 mg q.d. for 12 or 24 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Trial: 27153246
Drug: faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: faldaprevir 240 mg q.d. for 12 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Trial: 27153246
Drug: faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: faldaprevir 240 mg q.d. for 24 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks